Global Gene Panel Market- By Product & Service (Test Kits and Testing Services), By Technique (Amplicon Based Approach and Hybridization Based Approach), By Design (Predesigned Gene Panel and Customized Gene Panel), By Application (Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics, and Other Applications), By End-User (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, and Hospital & Diagnostic Laboratories), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

Report Overview

The Global Gene Panel Market size is expected to be worth around USD 2,454 Million by 2022 from USD 9,345 Million in 2032, growing at a CAGR of 14.7% during the forecast period from 2022 to 2032.

A test that aids in the simultaneous analysis of multiple genes for cancer-associated mutations is referred to as a gene panel. This test can examine a large number of genes, which helps learn more about cancer and provides a safe diagnostic that can help stop cancer from spreading. Two types of genes, BRCA1 and BRCA2, are responsible for the production of proteins that aid in tumor suppression, stop the growth of tumor cells, and repair damaged DNA.

The market is expanding as a result of a number of factors, including the rising demand for genetic screening, the increasing incidence of hereditary disorders and cancer, and the development of genetic screening recommendations in order to take presumptive measures that effectively reduce the mortality rate caused by genetic disorders.

In addition, in order to make a decisive step toward disease therapeutics and prognostics, clinicians now prioritize gaining an understanding of the genetic predisposition of any type of cancer or other genetic disorder that is known to exist.

*Actual Numbers Might Vary In The Final Report

Key Takeaways

• The Gene Panel Market was valued at USD 2,454 Million in 2022.
• It is projected to reach a value of USD 9,345 Million by 2032.
• The Compound Annual Growth Rate for the market is 14.7% over the forecast period 2023-2032.
• Gene panels are used to examine a large number of genes that can help understand more about cancer, including two types of genes, BRCA1 and BRCA2.
• By Product and service, the test kit segment had a revenue share of 54% in 2022.
• The predesigned gene panel segment held over 68% of the market for biopsy devices.
• In 2022, North America dominated the gene panel market with the highest revenue share of 45%.
• The amplicon-based approach segment is growing at the highest CAGR from 2023 to 2032.
• The research & academic institutes segment held the highest revenue share of the gene panel market.
• The cancer risk assessment segment dominated the gene panel market in terms of application.
• By Design, the predesigned gene panel segment held over 68% of the market for biopsy devices.

By Product & Service Analysis

The Test Kit Segment Holds the Largest Share of the Market.

Because of major factors like the increasing rate of technological advancement over the past few years, which has provided numerous opportunities for the industry to expand, the test kits segment continues to hold the dominant share of 57.9%. The exponential growth of the market is aided by the making of custom gene panel test kits for specialized therapeutic areas and the rise in the prevalence of chronic diseases.

The rapid acceptance of these tests throughout the world can be attributed to the government’s increasing emphasis on governing & raising awareness about them. A strong entry channel for new market entrants has been created by rising support for R&D and major market players’ strong market positions.

By Technique Analysis

Amplicon-based approach accounted for the Highest Market Share

Amplicon-based approach accounted for the largest market share of 62%. The amplicon-based process is a well-liked target-based method for next-generation sequencing that looks at genetic differences in a particular genomic region. The amplicon-based way is helpful for validating CRISP, finding an inherited SNP, genotyping through sequencing, and finding indels (insertions and deletions).

For use with NGS technology, there are numerous commercially available gene panels based on amplicon sequencing. In addition, segment expansion is likely to be accelerated by the increasing number of product launches by 2032.

In terms of complexity and uniformity, the hybridization approach produces the best results. When sequencing a large number of genes, this is advantageous. Due to its dependability and reproducibility, the hybridization-based method is frequently utilized for multigene panels in various clinical settings.

By Design Analysis

The Predesigned Gene Panel Segment Led to the Highest Market Share

With the highest market share, the predesigned gene panel segment is expected to grow significantly during the forecast period. It is always suggested that predesigned gene panels be used for consumer genetic testing to produce a comprehensive analysis because humans are still at the emerging level of understanding genetic predisposition to any disorder. Even though the idea of customizable gene panels is interesting, doctors always prefer to use genetic tests that have been thoroughly researched and comprehended.

During the forecast period, custom gene panels are anticipated to have a lower CAGR than predesigned panels. Customized gene panels are utilized to diagnose rare disorders for various research projects that require a more in-depth comprehension of a particular rare gene disorder. A well-known gene may be included in the gene panel to determine how it contributes to the disease.

By Application Analysis

The Cancer Risk Assessment Segment Dominated the Market.

Due to the minimally invasive nature of gene panels and an unprecedented rise in cancer incidence worldwide, the cancer risk assessment segment held the largest market share. Gene panels can effectively replace multiple screening tests to discover genetic risk factors for various types of cancer. This is because cancer screening is highly recommended for commonly occurring types of cancer in populations with hereditary risk factors.

In the coming years, gene panels are expected to be used to diagnose congenital diseases. A condition that begins at birth is known as a congenital disorder. Congenital disorders can be passed down through the family or brought on by the environment. During the forecast period, segment growth will likely be boosted by the rising prevalence of such conditions.

By End-User Analysis

The Research and Academic Institutes Segment had the Highest Revenue Share

The research & academic institutes segment accounted for the largest share of the market. Research and development activities are likely to increase as a result of factors like the worldwide rise in genetic disorders and cancer, which will present the sector with favorable growth opportunities.

In addition, as more and more screening procedures are recommended, people are now extremely wary of passing on genetic disorders to future generations. Along with gene panels for pre-gestational, gene panels for cancer screening, neonatal and prenatal screening procedures are gradually increasing their market penetration.

During the forecast period, hospitals and diagnostic laboratories are expected to experience a significant CAGR. Because its results provide insight into the distinctive contribution of genes to the cause of a particular disease, genetic analysis has emerged as the preferred diagnostic step for clinicians. Due to increasing recommendations and nationwide screening programs launched by various nations around the world, the use of gene panels in hospitals and diagnostic centers is on the rise.

Key Market Segments

Based on Product & Service

• Test Kits
• Testing Services

Based on Technique

• Amplicon Based Approach
• Hybridization Based Approach

Based on Design

• Predesigned Gene Panel
• Customized Gene Panel

Based on Application

• Cancer Risk Assessment
• Syndrome Specific
• High Penetrance
• High & Moderate Penetrance
• Comprehensive Cancer Risk
• Diagnosis of Congenital Diseases
• Pharmacogenetics
• Other Applications

Based on End-User

• Academic & Research Institutes
• Pharmaceutical & Biotechnology
• Hospital & Diagnostic Laboratories

Drivers

The Increasing Number of Product Launches and Approval Is Expected to Drive the Growth of the Market

Over the forecast period, the gene panel market is anticipated to expand due to the rising prevalence of chronic diseases linked to genes, such as heart attack, stroke, arthritis, cancer, and others. The International Agency for Research on Cancer (IRAC) estimates that there will be more than 27.5 million new cases of cancer, primarily as a result of unhealthy lifestyle choices like a lack of physical activity and smoking.

In addition, according to the World Health Organization, the United States reported over 795,000 strokes annually. It is expected to open up opportunities for the market for gene panels as a clinical diagnostic tool. Over the course of the forecast period, the expansion of the global gene panel market is anticipated to be fueled by an increasing number of product launches and approvals. EpiPanelDx PLUS, a gene panel test for the diagnosis of epilepsy, will be available from Bionano Genomics, an American manufacturer of genomic diagnostics.

Restraints

The Inability of Next-Generation Sequencing Gene Panels May Hampered the Market’s Growth

Due to their inability to detect some allelic mutations, next-generation sequencing (NGS) gene panels may hinder the growth of the gene panel market. The Scientific Electronic Library Online article discovered that NGS-based gene panels could not detect some allelic mutations associated with lysosomal storage disorders (LSD).

Opportunities

A Rise in the Need for Transplant Organs Will Drive the Growth of the Market

To rule out any possibility of any kind of genetic discrepancy that could be the cause of various genetic disorders, including cancer, researchers and clinicians strongly recommend prenatal, pre-gestational, and neonatal screening. A prequel, by Myriad Genetics, is a prenatal test that can be carried out as soon as 10 weeks into the pregnancy to determine the likelihood that an embryo will have Down syndrome.

The global demand for transplants like liver, kidney, and bone marrow transplants is also driving up demand for gene panels that can perform HLA typing. Gene panels are also anticipated to replace laboratory-based conventional genetic analysis technologies in the market.

Regional Analysis

North America Dominates the Global Gene Panel Market During the Forecast Period

In 2022, North America held the largest share of more than 45% of the global market, and it is anticipated to expand profitably over the course of the forecast. Gene panels in the United States are intended for the blood samples to be complementary to recommended genetic screening with the assistance of machine learning and to identify multiple genetic disorders.

The majority of the market expansion can be attributed to extensive research that was carried out in numerous research institutes that were jointly funded by academic research institutes, industry giants, the National Cancer Institute (NCI), and others across the country.

In Europe, along with an increase in the need for presumptive screening, there is a rise in genetic-level understanding of a disease. Due to the increasing demand for gene panels for different applications, industrial developments were occurring in the region.

Key Regions

• North America
  • The US
  • Canada
  • Mexico
• Western Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Portugal
  • Ireland
  • Austria
  • Switzerland
  • Benelux
  • Nordic
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • The Czech Republic
  • Greece
  • Rest of Eastern Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Australia & New Zealand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Colombia
  • Chile
  • Argentina
  • Costa Rica
  • Rest of Latin America
• Middle East & Africa
  • Algeria
  • Egypt
  • Israel
  • Kuwait
  • Nigeria
  • Saudi Arabia
  • South Africa
  • Turkey
  • United Arab Emirates
  • Rest of MEA

Key Players Analysis

Centogene N.V. Declared the Expansion of its Collaboration with Agios Pharmaceuticals, Inc.

The market’s major players are concentrating on strategic collaborations and partnerships and expanding into economically prosperous regions. Centogene N.V. announced the expansion of its partnership with Agios Pharmaceuticals, Inc. to develop better PYRUKYND therapies for genetically confirmed diseases. The US Food and Drug Administration (FDA) granted approval to PYRUKYND, a first-in-class, selective, small-molecule activator of the pyruvate kinase enzyme.

A few prominent players in the market are Integrated DNA Technologies, Inc., F. Hoffmann-La Roche AG, Eurofins Scientific, GATC Biotech AG, Hoffmann-La Roche Ltd, Novogene Co., Ltd., CENTOGENE AG, Personalis, Inc., and other key companies.

Market Key Players

• Agilent Technologies, Inc.
• Thermo Fisher Scientific
• Bio-Rad Laboratories, Inc.
• Illumina, Inc.
• Qiagen
• Foundation Medicine, Inc.
• Guardant Health
• Myriad Genetic Laboratories, Inc.
• Cepheid
• Other Key Players

Key Industry developments

• In April 2021- Illumina and Kartos announced a new oncology partnership to develop TP53 Companion diagnostics based on NGS that can aid in cancer diagnosis.
• In May 2022– Gene2Me introduced a variety of NGS-based panels for oncology detection, personalized medicine, and the detection of hereditary diseases.

Report Scope